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Abstract  
Identification of sequence variants robustly associated with predisposition to diabetic 
kidney disease (DKD) has the potential to provide insights into the pathophysiological 
mechanisms responsible. We conducted a genome-wide association study (GWAS) of DKD in 
type 2 diabetes (T2D) using eight complementary dichotomous and quantitative DKD 
phenotypes: the principal dichotomous analysis involved 5,717 T2D subjects, 3,345 with 
DKD. Promising association signals were evaluated in up to 26,827 subjects with T2D (12,710 
with DKD). A combined (T1D+T2D) GWAS was performed using complementary data 
available for subjects with T1D, which, with replication samples, involved up to 40,340 
diabetic subjects (and 18,582 DKD cases).  
Analysis of specific DKD phenotypes identified a novel signal near GABRR1 (rs9942471, 
p=4.5×10
-8
) associated with ‘microalbuminuria’ in European T2D cases. However, no 
replication of this signal was observed in Asian subjects with T2D, or in the equivalent T1D 
analysis. There was only limited support, in this substantially enlarged analysis, for 
association at previously-reported DKD signals, except for those at UMOD and PRKAG2, both 
associated with ‘eGFR’.  
We conclude that, despite challenges in addressing phenotypic heterogeneity, access to 
increased sample sizes will continue to provide more robust inference regarding risk-variant 
discovery for DKD. 
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Introduction 
Progressive loss of renal function represents one of the most serious complications of 
diabetes, yet strategies for prevention and management are suboptimal. One of the 
principal obstacles to improved clinical interventions remains rudimentary understanding of 
the processes whereby sustained exposure to elevated levels of glucose (and/or other 
manifestations of the diabetic state) leads to progressive disturbance of renal morphology 
and function (1). 
There is considerable variation in the progression and severity of renal complications of 
diabetes (collectively, diabetic kidney disease [DKD]). The prevalence of DKD in subjects with 
T2D is ~30-50%: some patients experience a relatively rapid decline in renal function, whilst 
others maintain normal renal function despite decades of suboptimal glycemic control (2). 
The factors influencing this variation in outcome have not been fully characterised, but 
substantial evidence supports a genetic contribution. As in type 1 diabetes (T1D), DKD in 
those with type 2 diabetes (T2D) aggregates in families (3, 4), and the prevalence of DKD in 
T2D differs considerably between ethnic groups (5-7).  
These observations indicate that the identification of genetic variants influencing DKD 
predisposition should accelerate characterization of the biological basis of DKD. In contrast 
with most complex multifactorial traits, efforts to apply candidate gene and genome wide 
association studies (GWAS) approaches to DKD have met with limited success (8-11). Many 
genetic associations have been reported, but few robustly replicated loci have emerged. 
This likely reflects the comparatively small sample sizes of previous studies, such that power 
would have been limited to detection of common loci of unusually large effect. In the case 
of DKD in T2D, this is likely to have been compounded by the heterogeneity of the 
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phenotype: autopsy studies indicate that only ~50% of chronic kidney disease (CKD) in T2D 
can be attributed to classical diabetic nephropathy (12). The success of equivalent GWAS 
efforts for CKD (for which several replicated loci have been described) provides reassurance 
that it is possible to identify variants with broad impact on the progression of renal disease, 
irrespective of the dominant pathology (13).  
Reduced kidney function, reflected by the estimated glomerular filtration rate (eGFR) and 
end-stage renal disease (ESRD), and dysfunction of the glomerular filtration barrier, 
reflected by albuminuria, can develop independently. This suggests that the two cardinal 
features of DKD involve distinct disease mechanisms and may be subject to different genetic 
effects. Albuminuria is known to be a poor predictor of diabetes-related ESRD, especially in 
the early stages, and regression to normoalbuminuria is common in patients with 
microalbuminuria (14).  
These observations provide confidence that the combination of increased sample size and 
improved definition of DKD phenotypes should enable risk-variant detection and uncover 
mechanisms that contribute to renal dysfunction in diabetes. In particular, the separation of 
cases into phenotypic classes based on disease stage and/or phenotype manifestations, 
incorporating information on both albumin excretion and eGFR, can be expected to increase 
etiological homogeneity and augment power for locus identification (14-16). 
The SUMMIT (SUrrogate markers for Micro- and Macro-vascular hard endpoints for 
Innovative diabetes Tools) consortium adopted such a strategy to perform a GWAS for DKD 
in subjects with T1D (17). Here, we report on equivalent analyses conducted in the context 
of T2D, as well as those from a combined (T1D+T2D) analysis involving up to 40,340 
subjects.  
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Methods 
Diabetic kidney disease phenotype definitions 
Not all patients with DKD will develop every form of the disease or progress to the most 
severe stage of ESRD. Dysfunction of the glomerular barrier, represented by albuminuria, 
and reduced kidney function, represented by eGFR, can develop independently. To explore 
the disease severity spectrum and the different disease processes represented by eGFR and 
albuminuria, we defined seven binary phenotypes using clinical measures of albumin 
creatinine ratio (ACR), AER and eGFR (Table 1 [T2D-only] and Supplementary Table 8 
[T1D+T2D]). The phenotype definitions were aligned to other large-scale genetic studies of 
T1D-DKD in SUMMIT (17) and the Diabetic Nephropathy Collaborative Research Initiative 
(DNCRI) (18). The definition of chronic kidney disease was also aligned to that used by the 
CKDGen consortium (eGFR<60 mL/min/1.73m
2
) although we restricted cases and controls to 
those with diabetes (13).  
We used AER measured over-night (µg/min), during 24 hours (mg/24 h), or as a spot 
measurement of ACR (mg/mmol) or eGFR calculated using the Modification of Diet Renal 
Disease Study Group (MDRD) formula (eGFR=32788 x Serum Creatinine (μmol/L)
-1.154
 x Age
-
0.203 
x [0.742 if female]) to classify disease stage and severity. We based the control 
definition on either AER or ACR as most studies had measured either. In the studies that had 
measured both, 2/3 measures for AER and ACR had to meet the control criteria (Table 1). 
We were unable to exclude albuminuric patients that presented as normoalbuminuric due 
to prescribed renin-angiotensin system blockers. Since reduced kidney function (reflected 
by eGFR) and dysfunction of the glomerular filtration barrier (reflected by albuminuria) can 
develop independently, we did not exclude individuals with albuminuria from the controls 
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for the eGFR-defined phenotypes and vice versa. In subjects with T2D, ~46% of 
normoalbuminuric controls had an eGFR<60 mL/min/1.73m
2
 (1,098/2,372). 
In all, we defined seven dichotomous phenotypes: 
• the ‘all DKD’ phenotype, our primary phenotype, designed to capture the broadest 
set of DKD phenotypes;  
• the ‘microalbuminuria’ phenotype (equivalent to ‘early DKD’ from Sandholm et al, 
2017) (17) to identify variants that contribute to early dysfunction of the glomerular 
barrier;  
• the ‘late DKD’ phenotype to identify variants that contribute to severe glomerular 
barrier dysfunction;  
• two ‘ESRD’ related phenotypes focused on identification of variants associated with 
end stage renal failure, comparing those with ESRD either to control subjects 
without any DKD (‘ESRD vs controls’) and relative to control subjects without ESRD 
(‘ESRD vs no ESRD’);  
• the chronic kidney disease (‘CKD’) phenotype to identify variants that contribute to 
reduced kidney function (eGFR);  
• the ‘CKD and DKD’ phenotype to identify any variants that may contribute to the 
development of kidney disease irrespective of glomerular barrier dysfunction or 
reduced kidney function; and  
•  estimated glomerular filtration rate (‘eGFR’), a continuous phenotype, to identify 
variants that play a role in kidney function that may not be detected by the analysis 
of the binary DKD phenotypes. The eGFR measures were not transformed as they 
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approximated a normal distribution (Supplementary Figure 1). 
Study populations  
We identified DKD cases and controls in subjects with T2D from the Scania diabetes registry 
(SDR) (19), the Genetics of Diabetes and Audit Research in Tayside Scotland (GoDARTS) 
study (20), the Steno Diabetes Centre (21) and the BENEDICT (Bergamo Nephrologic 
Diabetes Complications Trial, Italy) A and B studies (22). We identified independent 
replication studies in populations of European descent (deCODE, the Family investigation of 
nephropathy and diabetes [FIND] study, the DIabetes REgister in VAsa region [DIREVA] 
study, the Diagnostic Optimization and treatment of diabetes and its complications in the 
Chernihiv region [DOLCE] study, the Malmo Diet and Cancer Study [MDC], Inter99, Vejle 
Diabetes Biobank and the Anglo-Danish-Dutch study of Intensive Treatment In PeOple with 
screeN detected diabetes in primary care [ADDITION]), and Asian descent (RIKEN, the 
Singapore Diabetic Cohort Study [SDCS], the Hong Kong Diabetes Registry [HKDR] and the 
Singapore Study of Macro-angiopathy and Micro-vascular Reactivity in Type 2 Diabetes 
[SMART2D] study) (Supplementary Table 1). 
We combined the subjects with T2D with non-overlapping samples from the study of DKD in 
subjects with T1D (17). Replication studies (of DKD in subjects with T1D) (17), were also 
used for replication in the combined analysis of T1D+T2D (Supplementary Table 1). None of 
these studies overlapped with samples included in the analysis of eGFR and CKD by the 
CKDGen consortium (13). 
Genome-wide genotyping and imputation  
The T2D discovery cohorts were genotyped on the Affymetrix SNP 6.0, the Illumina Omni 
express array and the Illumina 610Quad arrays (Supplementary Table 4). Individual study 
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centres excluded SNPs for minor allele frequency (MAF) <1%. SNPs with a MAF 1-5% were 
excluded if the Hardy-Weinberg equilibrium (HWE) test p<1×10
-4
 or the call rate <99%. SNPs 
with MAF ≥5% were excluded if the HWE p<5.7×10
-7
 or the call rate <95% (23). Samples 
were excluded if: their call rate was <95%; genotype heterozygosity was >3SD from the 
study sample mean; or they failed gender checks. Based on principal component analysis: 
population outliers were removed if they were not of European descent (compared to the 
1000G populations) or fell >3SD away from the population means of the first two principal 
components for samples of European descent. Duplicates were removed but related 
individuals were retained for genotype imputation.  
Genotypes were prephased using SHAPE-IT (v2) (24) and imputed using IMPUTEv2
 
(25) 
against the March 2013 1000G version 1 reference panel using standard protocols and 
recommended settings.  
Replication genotyping 
Direct typing of twelve SNPs (rs11622435, rs12917707, rs17421627, rs1989248, rs2194025, 
rs2206136, rs4977388, rs61277444, rs6865390, rs7222331, rs9939609 and rs9942471) was 
performed in DIREVA samples using TaqMan allelic discrimination assays according to the 
manufacturer’s protocol (Applied Biosystems, Carlsbad, CA). Sequenom multiplex 
genotyping was performed for the same SNPs in DOLCE using the standard protocol (26).  
Statistical analysis 
Heritability of diabetic kidney disease phenotypes 
Narrow sense heritability was estimated by GCTA (v1.26) (27) from 4.5 million directly typed 
and imputed markers (info>0.75) in GoDARTS (Supplementary Table 1) for ‘all DKD’, ‘CKD’ 
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and ‘eGFR’. The sample size for these phenotypes exceeded the recommended threshold for 
reliable heritability estimates (N=3,160 based on a standard error ≤ 0.1) (28).  
Genome-wide association analysis 
Genome-wide association analyses were performed by individual study centres using an 
additive model whilst correcting for age, gender and duration of diabetes. We estimated 
allelic effects using the score test from SNPTESTv2 in unrelated samples for dichotomous 
traits (29). Association p values were calculated using EMMAX from a larger sample of 
related individuals whilst correcting for a kinship matrix (30). For ‘eGFR’ we estimated allelic 
effects and association p values using EMMAX (30).  
Power calculations 
We performed power calculations for dichotomous traits based on a MAF of 8%, an allelic 
OR range 1.05-2.00, and α=5×10
-8 
(genome-wide significance). The power calculations were 
performed, for the discovery meta-analysis of ‘all DKD’, separately for the T2D-only (3,345 
DKD cases and 2,372 DKD controls) and the combined (T1D+T2D; 5,908 DKD cases and 4,965 
DKD controls) meta-analyses 
At α≤5×10
-8
, we had >80% power to detect an allelic OR>1.40 in the T2D-only discovery 
analysis (Supplementary Figure 2C) and an allelic OR>1.25 (Supplementary Figure 2B) in the 
combined discovery analysis. We also performed power calculations for the reported DKD 
loci, as above, but using α=9×10
-4 
(this α accounts for the number of loci tested but not the 
number of phenotypes analysed). In the combined analysis (T1D+T2D, ‘all DKD’) we had 
>80% power to detect variants with an allelic OR>1.20 (Supplementary Figure 2A). 
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Discovery meta-analysis 
Two discovery meta-analyses were performed: one that included summary statistics 
estimated from subjects with T2D-only and a second that combined T2D-only analyses with 
equivalent analyses in subjects with T1D (17). Individual study summary statistics were 
centrally filtered for a minor allele count in either cases or controls <10 and an info score 
<0.4 for imputed variants.  
EMMAX p values were combined in a sample size weighted z-statistic meta-analysis using 
METAL (version 25/03/2011) (31). Effect estimates were combined in a fixed-effect-inverse-
variance weighted meta-analysis using GWAMA (v2.1) (32). Meta-analysis results were 
restricted to allelic effects estimated in ≥ two studies. For binary traits, independent variants 
(>100Kb apart) were selected for replication from the T2D-only analysis based on 
association p≤5×10
-6
 and from the combined (T1D+T2D) analysis based on p≤1×10
-6
. For 
‘eGFR’, SNPs were chosen for replication based on association p≤5×10
-6
 in subjects with T2D 
or p<1×10
-6
 in the combined analysis. SNPs associated with ‘eGFR’ at p≤5×10
-4
 in either 
‘eGFR’ analysis (T2D only or T1D+T2D) which had also been reported at p≤5×10
-8
 with eGFR 
by the CKDGen consortium were also included in the list of SNPs for replication (13).  
Replication 
We sought replication for 164 lead variants in thirteen studies of T2D-DKD for which it was 
possible to obtain in silico replication from available GWAS data or replication from where 
de novo genotyping (DIREVA and DOLCE) (Figure 1). Replication studies aligned their DKD 
phenotypes with those employed in the SUMMIT GWAS. Although association results for 
the lead variants were recovered for all compatible DKD phenotypes available in the 
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replication samples (Supplementary Table 1), joint meta-analysis results were reported for 
those phenotypes where the primary GWAS associations exceeded the thresholds above.  
As with the discovery, meta-analysis effect estimates from replication studies were 
combined using GWAMA (v2.1) (32), and EMMAX p values using METAL (version 
25/03/2011) (31).  
Known DKD variants 
We examined the literature for variants that have been associated with DKD from candidate 
gene (p<0.05) and GWA (p≤5×10
-8
) studies. Sixty-one variants were identified and aligned to 
the reported risk allele for binary traits (or the trait-raising allele for quantitative traits). We 
assessed both direction of effect and strength of association in the present study for those 
phenotypes that most closely matched the original report (but irrespective of type of 
diabetes).  
Genetic risk score analysis 
We included variants (p≤5×10
-8
) from GWAS to generate genetic risk scores (GRS) for: 
coronary artery disease (CAD) (33); body mass index (BMI) (34); waist-hip-ratio adjusted for 
BMI (WHR) (35); low-density lipoprotein cholesterol (LDL-C); triglycerides (TRIG); high-
density lipoprotein cholesterol (HDL-C) (36); fasting insulin (FI); insulin resistance (IR) (37-
39); fasting glucose (FG) (38); T1D (40); T2D (41); and systolic blood pressure (SBP) (42). The 
relationship between the GRS and the DKD phenotype was calculated using an inverse-
variance weighted method described in Ehret et al., 2011(42).   
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Results  
DKD definitions: We considered seven dichotomous phenotypes designed to capture the 
spectrum of DKD (see Methods), and ‘eGFR’. We aimed to identify variants that influence 
multiple stages in DKD progression, as well as those that have more stage-specific effects. 
The principal definition (‘all DKD’) included 3,345 T2D subjects with any form of DKD 
(ranging from microalbuminuria through to ESRD) as cases, and 2,372 T2D subjects, 
normoalbuminuric despite >10 years duration of diabetes, as controls. The other six 
dichotomous phenotypic comparisons are described in Table 1 (see also Methods).  
Contribution of Genetic Variants to DKD: The genetic variation, explained by the SNPs on 
the genotyping array and estimated using GCTA (v1.26) (30) in up to 6,335 subjects with T2D 
from the GoDARTS, was highest in ‘CKD’ (h
2
=0.12) and similar for ‘all DKD’ (h
2
=0.08) and 
‘eGFR’ (h
2
=0.07) (Supplementary Table 2). We restricted analyses to phenotypes with 
sample sizes deemed sufficient for accurate estimation of heritability (N≥3,160 to obtain an 
SE≤0.1) (28). 
GWAS for DKD in T2D: The DKD discovery analysis combined GWAS data from four studies 
of European descent: GoDARTS (20), SDR (19), STENO (Denmark) (21) and the BENEDICT 
study (phases A and B, Italy) (22) (Table 1, Supplementary Table 3). For the principal (‘all 
DKD’) analysis, the sample size of the discovery T2D-only meta-analysis had >80% power to 
detect variants with MAF≥8% and allelic OR>1.40 (Supplementary Figure 2C). The number of 
variants meta-analysed for each DKD phenotype varied between 5,864,445 in the ‘ESRD vs 
no ESRD’ phenotype and 9,263,264 in the ‘all DKD’ phenotype (Supplementary Table 4). 
These differences reflect the minor allele count exclusion filter. 
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Manhattan and QQ plots of discovery p-values for each of the eight DKD phenotypes were 
well calibrated, and several showed a modest excess of significant associations 
(Supplementary Figure 3). In the discovery GWAS, only one locus reached genome-wide 
significance: PLCB4 (encoding 1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase 
beta-4) on chromosome 20. The lead variant rs2206136 was associated with the ‘CKD’ 
phenotype (EAF 42%; OR 1.20 [1.08, 1.34]; p=2.1×10
-8
) (Table 2; Supplementary Figure 3A).  
To extend power to detect associations of lesser effect, and to replicate the PLCB4 
association, we identified 139 loci with SNP associations exceeding p≤5×10
-6
 in at least one 
of the seven dichotomous DKD analyses. We also identified 22 loci (25 lead variants) for 
replication from the ‘eGFR’ analysis (based on either p<5×10
-6
 in our ‘eGFR’ analyses alone, 
or p<5×10
-4
 in our analysis and a genome-wide association [p<5×10
-8
] reported by the 
CKDGen consortium) (Supplementary Figure 3Q) (13). We sought replication for 164 lead 
variants in thirteen studies of T2D-DKD (nine involving European subjects, and four involving 
Asian subjects) for which it was possible to obtain association analyses based on either in 
silico (from existing GWAS) or de novo genotyping (Figure 1). Replication studies recoded 
their DKD phenotypes to align definitions with those employed in the SUMMIT GWAS. 
Although association results for the lead variants were recovered for all compatible DKD 
phenotypes available in the replication samples (Supplementary Table 1), joint meta-
analysis results are reported for only those phenotypes where the primary GWAS 
associations exceeded the thresholds above (Supplementary Table 5). The replication 
samples available for the ‘all DKD’ phenotype included up to 3,999 T2D subjects of European 
ancestry (1,270 cases) and 17,111 (8,095 cases) from Asia (Supplementary Table 1).  
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The ‘CKD’ association near PLCB4 did not replicate in either European or Asian data (joint 
analysis ; ORAsian+Euro 1.12 [1.05, 1.19]; p=2.1×10
-4
) (Table 2). Joint analysis of dichotomous 
DKD phenotypes identified one novel SNP association that marginally exceeded genome-
wide significance (p=5×10
-8
, without adjustment for the multiple GWAS we performed) 
(Table 2). This signal, on chromosome 6, is centred on rs9942471 and lies ~7kb upstream of 
GABRR1 (encoding the rho1 subunit of the GABA type a receptor). The major allele was 
associated with increased risk of ‘microalbuminuria’ in subjects of European ancestry (Joint 
analysis; EAF 64%; OREuro 1.25 [1.16, 1.34]; p=4.5×10
-8
) (Figure 2, Table 2). Associations of 
rs9942471 with other DKD phenotypes are given in Supplementary Table 6.  
Rs9942471 is in high LD (r
2
>0.8) with the lead eQTL variant for GABRR1 expression in artery, 
oesophagus and skin (p≤4×10
-8
) and the major allele is associated with decreased expression 
(42). However, there was no evidence for replication of this SNP in T2D subjects of Asian 
ancestry only (EAF 90%; ORAsian 0.99 [0.87, 1.13]; p=0.91) although the higher frequency of 
the effect allele in Asians (90%) compared to Europeans (64%) reduces the power to detect 
an effect in subjects of Asian descent. Ethnic differences in regional LD could have 
contributed to failed replication: rs9942471 may be a better marker of the shared causal 
variant in subjects of European descent. However, this seems unlikely given broad similarity 
of LD patterns across subjects of European and Asian descent (estimated separately from 
the 1000G population).  
Replication samples for the ‘eGFR’ phenotype included 8,749 subjects of European and 
9,071 subjects of Asian ancestry with T2D (Figure 1). Joint analysis of discovery and 
replication results captured the well-established association with variants near UMOD 
(uromodulin), centred on rs11864909 (βAsian+Euro 2.34 [1.68, 3.00] mL/min/1.73m
2
; p=4.4×10
-
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12
) (Table 2). There was no difference in effect by diabetes type: the effect estimate in 
subjects with T1D (βT1D 1.23 (-0.05, 2.51), p=0.06) overlapped the effect size in subjects with 
T2D (17). We also compared the effects of variants associated with DKD phenotypes in 
subjects with T2D from Table 1 with their effects in equivalent DKD phenotypes in subjects 
with T1D (17) (Supplementary Table 7). 
Combined T1D and T2D analysis: To increase power to detect loci that contribute to 
processes involved in the development of DKD irrespective of diabetes subtype, we 
combined the results from the primary GWAS meta-analysis for T2D-DKD phenotypes with 
those for the corresponding T1D-DKD phenotypes (Supplementary Table 4, 9) (17). The 
combined discovery meta-analysis of ‘all-DKD’ included 10,873 diabetic subjects of 
European descent (5,908 cases) and provided >80% power (α=5×10
-8
) to detect a SNP 
association with an allelic OR>1.25 for variants with MAF >8% (Supplementary Figure 2B). 
The number of variants meta-analysed ranged from 7,959,015 for ‘ESRD vs no ESRD’ to 
9,364,702 for the ‘all DKD’ phenotype (Supplementary Table 4).  
No significant associations were detected for dichotomous DKD phenotypes in the 
combined (T1D+T2D) meta-analysis (Supplementary Figure 4; Supplementary Table 9). The 
combined meta-analysis for ‘eGFR’ highlighted a novel genome-wide significant association 
involving a cluster of variants on chromosome 2 led by rs1974990 (EAF 8%; β 4.07 [2.61, 
5.52] mL/min/1.73m
2
; p=4.8×10
-8
) and mapping near SSB (encoding Sjogren syndrome 
antigen B) (Table 2).  
As in the T2D-only analysis, we selected 47 loci for replication (30 with p<1×10
-6
 with at least 
one of the DKD phenotypes) from the combined (T1D+T2D) GWAS, and an additional 17 loci 
from the equivalent analysis of ‘eGFR’. The combined association p-value for rs9942471 
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(‘microalbuminuria’; OR 1.10 [1.02, 1.19]; p=0.001) did not reach the threshold for 
replication. Lead variants at these 47 loci were tested for all DKD phenotypes available in 
the relevant replication samples in subjects with T1D or T2D (Supplementary Table 1): meta-
analysis results were only reported for those phenotypes that contributed to discovery-
stage associations. This joint, combined (T1D+T2D) analysis generated a substantially 
enlarged data set for the ‘all-DKD’ phenotype (40,640 subjects [18,582 cases]) (Figure 1). 
However, none of the variants selected for replication from the dichotomous phenotypes 
reached genome-wide significance (p≤5×10
-8
). 
The joint, combined analysis for ‘eGFR’ in subjects European and Asian descent included 
31,562 subjects, and replicated known associations near UMOD (rs11864909; βAsian+Euro 2.11 
[1.52, 2.70]; p=2.3×10
-12
) and PRKAG2 (rs10224002 βAsian+Euro 2.01 [1.30, 2.72], p=2.7×10
-8
) 
(Table 2; Supplementary Figures 5 and 6). The PRKAG2 was non-significant (p≤5×10
-8
) in 
individual analyses of ‘eGFR’ in T2D-only (βEuro 2.13 [1.28, 2.98]; p=8.5×10
-7
) or T1D-only 
(βEuro 1.23 [-0.19, 2.65]; p=0.09) and effect sizes did not differ by type of diabetes.  
The association at SSB, detected in the combined ‘eGFR’ analysis, did not replicate 
(rs1974990, β 0.04[-2.69, 2.76] mL/min/1.73m
2
; p=0.98) and, in the joint, combined analysis 
was no longer genome-wide significant (βAsian+Euro 3.17 [1.88, 4.45] mL/min/1.73m
2
; 
p=1.4×10
-6
) (Table 2).  
Evaluating previous association claims: Of the 61 published loci, for which there are 
published claims of association with T1D-DKD or T2D-DKD (8), 55 of these associations were 
represented by variants contributing to our meta-analyses of DKD phenotypes in either 
subjects with T2D-only or T1D+T2D. Two of these, the ‘eGFR’ associations at UMOD and 
PRKAG2, replicate at genome-wide significance in our data (Table 2). We tested the 
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association of the remaining 53 lead variants in the T2D-only and combined analyses 
(Supplementary Figure 6). Fourteen variants were associated with a DKD phenotype 
corresponding to the original report at nominal significance (p<0.05) but only 10 of these 
were directionally consistent with previous reports (Supplementary Table 10). At a more 
stringent significance level (p<9×10
-4
) that accounts for the 55 variants tested (but not the 
multiple phenotypic categories), only two variants were associated with a DKD phenotype 
that corresponded to the original report, both of them in the combined (T1D+T2D) analysis, 
and both directionally consistent with previous reports. These two SNPs were rs2838302, 
near SIK1, associated with ‘ESRD vs no ESRD’ (EAF 8%; OR 1.39 [1.12, 1.74]; p=3.9×10
-4
) and 
rs7583877, near AFF3, associated with ‘ESRD versus no ESRD’ (OR 1.22 [1.13, 1.32]; 
p=4.8×10
-4
) (Supplementary Table 10). When we took account of the substantial participant 
overlap between the original reports and the samples in the present study, apparent 
replications failed to reach nominal (p<0.05) significance (though, for these, the sample 
sizes available for independent replication were often small). Thus, other than the ‘eGFR’ 
associations at UMOD and PRKAG2, we found limited evidence in this study to corroborate 
previously-reported DKD associations, despite, for most variants, sample sizes considerably 
larger than those included in the original report. Validation of previously-reported DKD 
associations could be complicated by differences in phenotype definitions and/or analytical 
methods between this study and published reports. We could not assess whether the 
UMOD or PRKAG2 allelic effects were different in this study compared to those reported by 
CKDGen consortium as the allelic effects were not on the same scale (e.g. untransformed vs 
log transformed).  
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Genetic overlap with risk factors: Several exposures and diseases have been reported to 
increase DKD risk in epidemiological studies (1, 2, 43). To explore the extent to which these 
reflect shared genetic background, we constructed weighted genetic risk scores (GRS) for 
twenty traits related to diabetes (37, 39-41), insulin resistance (38), obesity (34, 35), 
hypertension (42), coronary artery disease (33), and lipids (36). These GRS, constructed from 
signals identified (p<5×10
−8
) in previously-published GWAS, included between 10 and 96 
SNPs per phenotype. We tested the association of these GRS with each of the DKD 
phenotypes from this study, in both T2D-only and combined (T1D+T2D) data sets (42).  
After Bonferroni correction (p≤2.5×10
-3
, which accounts for the number of trait GRS but not 
the number of DKD phenotypes): In subjects with T2D a GRS for increased waist-to-hip ratio 
(WHR) (p=4.8×10
-4
) was associated with increased risk of ‘ESRD vs no ESRD’; and a GRS for 
increased BMI was associated with ‘all DKD’ (p=1.8×10
-4
) and ‘late DKD’ (p=1.8×10
-3
) 
phenotypes. A similar pattern of association for the BMI GRS was observed in the combined 
(T1D+T2D) ‘all DKD’ analysis (p=2.4×10
-5
) (Supplementary Table 11 and Figure 3). This last 
result survives additional correction (α=1.6×10
-4
) for the 16 DKD phenotypic comparisons 
considered.  
There is evidence implicating insulin resistance in the pathogenesis of DKD, and we wanted 
to understand whether the BMI GRS associations might reflect obesity-related insulin 
resistance (44, 45). We focused on the effects two alternative GRS for insulin resistance on 
DKD. The first, comprising lead variants (N=10) associated with increased fasting insulin 
(BMI-adjusted) (37), was associated with increased risk of ESRD in subjects with T2D (‘ESRD 
vs no ESRD’ p=1.6×10
-3
; ‘ESRD vs controls’ p=1.7×10
-3
) (Supplementary Table 11 and Figure 
3). The second, comprising lead variants from 53 loci associated with high fasting insulin 
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(BMI-adjusted), low HDL-C and high triglycerides (39), failed to show any association with 
DKD phenotypes. These findings provide some support for the causal contribution of insulin 
resistance and obesity to DKD pathogenesis. However, there is potential that some of these 
effects reflect collider bias (46) and additional larger studies will be required to substantiate 
this inference.   
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Discussion 
This study represents the largest study of the genetic basis of DKD in subjects with T2D to 
date, extending previous reports with respect to sample size and range of DKD phenotypes. 
We aimed to overcome some of the limitations of earlier studies in this area, and to develop 
insights into the pathogenesis of DKD. Despite sample sizes that exceeded 40,000, the yield 
of novel discoveries was modest. There were no significant (p<5x10
-8
) genetic associations 
with ‘all DKD’ that was best-powered definition on sample size. The relatively large sample 
size came with increased phenotypic (and likely genetic) heterogeneity: it was for this 
reason that we examined a range of DKD phenotypes that might offer better power to 
detect genetic associations with more restricted phenotypic impacts.  
This approach successfully identified a novel locus, GABRR1 (led by rs9942471), for 
‘microalbuminuria’ in European subjects with T2D. The variants, near GABRR1, reached a 
level of significance (p<5x10
-8
) that has typically been associated with robust, reproducible 
association in common disease GWAS. GABRR1 expression is upregulated in renal biopsies 
form DKD subjects (compared to controls) and in other non-diabetic kidney diseases 
characterised by glomerular scarring and inflammation (47). The variants were associated 
with GABRR1 expression in aorta, oesophageal mucosa and skin in GTEx. However, we 
found no replication of the GABRR1 association in subjects of European ancestry with T1D-
DKD, nor amongst subjects of Asian ancestry with T2D, though differences in risk-allele 
frequencies between these two ancestries and the modest size of the replication datasets at 
this locus reduce the power of the latter analysis. Our overall assessment is that this 
association should be considered provisional until it is possible to undertake further rounds 
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of adequately-powered replication that could establish the definitive status of this variant 
and this locus should also be assessed for effects on DKD progression in longitudinal studies.  
Even in the absence of specific signals of association with DKD, it is possible to use the 
aggregate pattern of association across the genome to identify more subtle genetic effects. 
The GRS analyses described here provide genetic support for the causal contribution of 
obesity to the development of T2D-DKD. This echoes strong epidemiological data, and 
mirrors equivalent analyses in T1D-DKD (48, 49). However, we cannot exclude that these 
associations may partly reflect collider bias (46): subjects with high BMI are likely to have a 
longer duration of diabetes and thus a higher chance of developing complications. Analyses 
using genetic instruments (GRS) for variation in insulin sensitivity produced variable results 
with respect to T2D-DKD, but indicate that the BMI effects may be partially mediated via 
obesity-related insulin resistance (37). There is substantial epidemiological data to support 
this link between insulin resistance and DKD risk (44, 45).  
The modest yield of association signals, and the limited replication of previous claims of DKD 
association, emphasises challenges associated with the identification of DKD-risk variants. 
For many complex traits, these have been overcome through a combination of increased 
sample size and phenotypic precision. Published genetic association studies of DKD have 
often used different definitions of DKD, which makes replication of previous findings 
difficult. In this study, we used phenotype definitions aligned to those used in the study of 
DKD in subjects with T1D (17). Standardising the phenotype definitions in this way allowed 
for seamless combination of the GWAS data across the two studies and may streamline 
subsequent efforts to study the genetics of DKD. The phenotype definitions applied to this 
study address some of the challenges associated with increasing sample size while 
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maintaining phenotype precision, and should, in due course, support the identification of 
robust associations with DKD. It is clear that these phenotype definitions are not without 
limitations, in the absence of strong genetic signals we have few clues to which particular 
diagnostic configurations will be most productive for genetic discovery. Targeting the 
phenotypes that show the greatest heritability may provide a guide (14).  
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Table 1: Genome-wide association study characteristics by diabetic kidney disease phenotypes in subjects with type 2 and type 1 diabetes 
Analysis Case definition Control definition 
Subjects with type 2 
diabetes 
Subjects with type 1 
diabetes 
#Cases #Controls #Cases #Controls 
All Diabetic kidney 
disease (DKD) 
All DKD: Microalbuminuria OR Late DKD OR end-
stage renal disease (ESRD) 
Normoalbuminuria (Albumin excretion 
rate [AER] <20 µg/min OR AER <30 mg/24 
h OR ACR <2.5/3.5 mg/mmol for 
men/women) AND duration of T2D >10 
years
‡
 
3,345 2,372 2,563 2,593 
Microalbuminuria* 
Microalbuminuria: At least 2 out of 3 consecutive 
measurements with albumin excretion rate (AER) 
≥20 AND <200 µg/min OR AER ≥30 AND <300 mg/24 
hr OR albumin to creatinine ratio (ACR) ≥2.5/3.5 
AND <25/35 mg/mmol for men/women; 
Normoalbuminuria AND duration of T2D 
>10 years
‡
 
1,989 2,238
†
 806 2,593 
Late DKD 
Late DKD: At least one measurement with AER ≥200 
µg/min OR AER ≥300 mg/24 h OR ACR ≥25/35 
mg/mmol for men/women) or end-stage renal 
disease (ESRD, estimated glomerular filtration rate 
(eGFR) < 15 mL/min/1.73m
2 
OR kidney 
transplantation OR dialysis) 
Normoalbuminuria AND duration of T2D 
>10 years
‡
 
1,339 2,372 1,757 2,593 
ESRD vs. controls 
ESRD: eGFR<15 mL/min/1.73m
2
 or renal dialysis or 
kidney transplant 
No DKD AND duration of T2D >10 years
‡
 371 2,076 813 2,398 
ESRD vs. no ESRD ESRD (see above) No ESRD AND duration of T2D >10 years
‡
 371 4,471 813 3,995 
Chronic Kidney Disease 
(CKD) 
CKD: eGFR < 60 mL/min/1.73m
2
 No CKD AND duration of T2D >10 years
‡
 3,094 2,906 2,460 774 
CKD and DKD 
CKD and DKD: eGFR < 45 mL/min/1.73m
2
 AND all 
DKD 
No CKD AND no ESRD AND 
normoalbuminuria AND duration of T2D 
>10 years
‡
 
897 1,610 1,750 1,385 
eGFR 32788 x Serum Creatinine(μmol/L)
-1.154
 x Age
-0.203
 x [0.742 if female] (mL/min/1.73m
2
) 9,197 3,961 
*Equivalent to the ‘early DKD’ phenotype from Sandholm et al., 2017 (17); †Not all studies were able to define microalbuminuria (due to limited information 
on microalbuminuric status) thus the case and control number is smaller than ‘all DKD’ and ‘late DKD’;
 ‡
The duration of diabetes for subjects with T1D was 
>15 years
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Table 2: Five loci were associated (p≤5×10
-8
) with chronic kidney disease (‘CKD’), ‘microalbuminuria’ and estimated glomerular filtration rate 
(‘eGFR’) in subjects with type 2 diabetes (T2D) or the combined analysis of T2D and type 1 diabetes (T1D+T2D) 
CHR:BP Phenotype SNP Locus 
Discovery Replication Joint analysis 
EA/NEA 
(Info) 
EAF 
OR/Beta 
P Ancestry 
OR/Beta 
P 
OR/Beta 
P N 
(95%CI) (95%CI) (95%CI) 
20: 9351150 T2D ‘CKD’ 
rs2206136 
(PLCB4) 
A/T 
(0.98) 
 
2.1×10
-8
 
European 
1.02 
0.69 
1.13 
9.0×10
-5
 11,900 
1.20 (0.91,1.15) (1.05,1.21) 
0.42 (1.08-1.34) Asian and 
European 
1.03 
0.68 
1.12 
2.1×10
-4
 13,813 
  
(0.94,1.13) (1.05,1.19) 
6: 89948232 
T2D 
‘microalbu-
minuria’ 
rs9942471 
(GABRR1) 
A/C 
(0.99) 
 
2.1×10
-7
 
European 
1.32 
0.06 
1.25 
4.5×10
-8
 4,801 
1.24 (0.99,1.75) (1.16,1.34) 
0.64 (1.15-1.34) Asian and 
European 
1.11 
0.12 
1.15 
1.2×10
-5
 5,559 
  
(0.99,1.23) (1.08,1.23) 
16: 20400839 T2D ‘eGFR’ 
rs11864909 
(UMOD) 
T/C 
(1.00) 
 
2.7×10
-5
 
European 
2.22 
4.1×10
-5
 
2.31 
4.6×10
-9
 12,343 
2.42 (1.16,3.28) (1.54,3.09) 
0.28 (1.28-3.56) Asian and 
European 
2.30 
3.6×10
-8
 
2.34 
4.4×10
-12
 19,747 
  
(1.48,3.12) (1.68,3.00) 
2: 170646916 
T1D+T2D 
‘eGFR’ 
rs1974990* 
(SSB) 
G/T 
(0.98) 
 
4.8×10
-8
 
European No replication available 
4.07 
4.8×10
-8
 13,158 
4.07 (2.61,5.52) 
0.08 (2.61,5.52) Asian and 
European 
0.04 
0.98 
3.17 
1.4×10
-6
 14,828 
  
(-2.69,2.76) (1.88,4.45) 
7: 151415041 
T1D+T2D 
‘eGFR’ 
rs10224002 
(PRKAG2) 
A/G 
 
1.5×10
-4
 
European 
2.15 
5.8×10
-4
 
1.89 
3.4×10
-7
 20,495 
(0.92) 1.75 (0.93-3.37) (1.17,2.62) 
0.74 (0.85-2.66) Asian and 
European 
2.42 
3.2×10
-5
 
2.01 
2.7×10
-8
 22,165 
  
(1.28,3.56) (1.30, 2.72) 
16: 20400839 
T1D+T2D 
‘eGFR’ 
rs11864909 
(UMOD) 
T/C 
 
1.1×10
-5
 
European 
2.22 
4.1×10
-5
 
2.02 
2.1×10
-9
 16,304 
(0.99) 1.90 (1.16,3.28) (1.36,2.69) 
0.29 (1.05-2.74) Asian and 
European 
2.30 
3.6×10
-8
 
2.11 
2.3×10
-12
 23,708 
  
(1.48,3.12) (1.52,2.70) 
*rs1974490 was only available in the 1000G reference panel and was not imputed in the European studies used in the replications 
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Figures 
Figure 1: Eight diabetic kidney disease (DKD) phenotypes were analysed in subjects with type 
2 diabetes (T2D, blue boxes) and in a combined (green boxes) analysis of subjects with T2D 
or type 1 diabetes (T1D, yellow box). N indicates the total sample count for either the ‘all 
DKD’ (number of cases are given in brackets) or the ‘eGFR’ phenotypes and may vary by 
variant as well as by DKD phenotype. Replication was sought for 164 loci and 47 loci from 
each analysis respectively in subjects of European and Asian ancestry with either T1D or T2D.  
Figure 2: A) Manhattan plot of p values from the meta-analysis of allelic effect on ‘early 
diabetic kidney disease’ in subjects with type 2 diabetes of European descent. The red line 
represents genome-wide significance (p<5x10
-8
) and the blue line suggestive significance 
(p<1x10
-6
). The peak represented by rs9942471 (p=4.5x10
-8
), near GABRR1 is highlighted in 
orange; B) A forest plot of allelic odds ratio (OR) and imputation information scores (RSQ) 
from individual studies (Study) that contributed to the discovery and replication (DIREVA) 
analyses of rs9942471 in ‘microalbuminuria’; Rs9942471 genotypes were not available in 
Steno; and C) a Locuszoom plot of the signal near near GABRR1 led by rs9942471 that was 
associated with early diabetic kidney disease in European subjects with T2D. 
Figure 3: A heat map of genetic risk score associations with diabetic kidney disease (DKD) 
phenotypes in subjects with either type 1 diabetes or type 2 diabetes. A GRS for body mass 
index was significant after correction for multiple testing while other traits including systolic 
blood pressure were not associated with DKD phenotypes. Abbreviations used: chronic 
kidney disease (‘CKD’), end stage renal disease (‘ESRD’) and estimated glomerular filtration 
rate (‘eGFR’). 
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Figure 1: Eight diabetic kidney disease (DKD) phenotypes were analysed in subjects with type 2 diabetes 
(T2D, blue boxes) and in a combined (green boxes) analysis of subjects with T2D or type 1 diabetes (T1D, 
yellow box). N indicates the total sample count for either the ‘all DKD’ (number of cases are given in 
brackets) or the ‘eGFR’ phenotypes and may vary by variant as well as by DKD phenotype. Replication was 
sought for 164 loci and 47 loci from each analysis respectively in subjects of European and Asian ancestry 
with either T1D or T2D.  
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Figure 2: A) Manhattan plot of p values from the meta-analysis of allelic effect on ‘early diabetic kidney 
disease’ in subjects with type 2 diabetes of European descent. The red line represents genome-wide 
significance (p<5x10-8) and the blue line suggestive significance (p<1x10-6). The peak represented by 
rs9942471 (p=4.5x10-8), near GABRR1 is highlighted in orange; B) A forest plot of allelic odds ratio (OR) 
and imputation information scores (RSQ) from individual studies (Study) that contributed to the discovery 
and replication (DIREVA) analyses of rs9942471 in ‘microalbuminuria’; Rs9942471 genotypes were not 
available in Steno; and C) a Locuszoom plot of the signal near near GABRR1 led by rs9942471 that was 
associated with early diabetic kidney disease in European subjects with T2D.  
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Figure 3: A heat map of genetic risk score associations with diabetic kidney disease (DKD) phenotypes in 
subjects with either type 1 diabetes or type 2 diabetes. A GRS for body mass index was significant after 
correction for multiple testing while other traits including systolic blood pressure were not associated with 
DKD phenotypes. Abbreviations used: chronic kidney disease (‘CKD’), end stage renal disease (‘ESRD’) and 
estimated glomerular filtration rate (‘eGFR’).  
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Online supplementary materials 
S1 Table 1: Table of phenotypic characteristics 
www.well.ox.ac.uk/~nvanzuy/Onlinesupp.S1Table1.xlsx 
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 S1 Table 2: Narrow sense (‘chip’) heritability of diabetic kidney disease phenotypes in subjects with type 2 diabetes estimated in the GoDARTS study  
Phenotype* Cases Controls h2 SE pval 
Chronic kidney disease 1,997 2,066 0.12 0.05 8.2×10-3 
All diabetic kidney disease 1,744 1,496 0.08 0.07 0.12 
Estimated glomerular filtration rate 6,335 0.07 0.03 9.8×10-3 
*All cases are compared to subjects with type 2 diabetes and normoalbuminuria or an estimated glomerular filtration rate >60 mL/min/1.73m2 unless 
otherwise stated. 
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S1 Table 3:  Study characteristics for studies included in the discovery meta-analysis of the primary ‘all diabetic kidney disease’ phenotype 
Diab
etes 
Cohort Cases
/contr
ols 
Age of onset of diabetes 
(cases/controls) 
Age 
(cases/cont
rols) 
%Males 
(cases/contr
ols) 
BMI 
(cases/ 
controls) 
HbA1c 
(cases/ 
controls) 
Duration of diabetes 
(cases/controls) 
2 SDR 1,250/
580 
54.5(12.6)/51.7(10.8) 65.5(11.7)/
67.8(10.5) 
65/52 30.2(5.3)/2
8.9(5.1) 
7.2(1.2)/
6.9(1.0) 
10.9(8.70/16.1(6.0) 
2 BENEDICT study 
phase A and B 
188/ 
165 
53.4(8.6)/49.3(8.4) 66.3(11.0)/
70.1(7.3) 
177/58 2938(4.8)/
27.8(4.1) 
6.0(1.4)/
5.8(1.4) 
12.(9.5)/20.8(6.0) 
2 STENO 163/ 
131 
46.1(9.2)/45.9(8.9) 61.2(7.5)/6
3.0(8.3) 
60/62 29.8(5.2)/2
7.3(4.5) 
9.1(1.7)/
8.8(1.3) 
15.3(7.1)/17.1(5.9) 
2 GoDARTS 1* 885/ 
816 
68.6 (9.1)/66.2(8.8) 58.9(12.3)/
54.0(12.1) 
53/52 31.0(5.5)/3
1.0(5.4) 
7.6(1.4)/
7.5(1.3) 
14.1(8.1)/16.5(6.8) 
2 GoDARTS2* 859/ 
680 
67.9(11.6)/66.2(10.8) 72.1(11.2)/
70.1(10.7) 
60/60 31.5(6.1)/3
1.2(6.1) 
7.5(1.5)/
7.5(1.3) 
11.4(6.9)/15.5(5.5) 
*GoDARTS was typed on two  genotyping arrays 
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S1 Table 4:  Table of genotypic characteristics: 
www.well.ox.ac.uk/~nvanzuy/Onlinesupp.S1Table4.xlsx 
S1 Table 5:  Replication was sought for 164 variants and results were returned for 108 of these variants for six dichotomous phenotypes and estimated 
glomerular filtration rate (eGFR, mL/min/1.73m2) in subjects with type 2 diabetes.  
www.well.ox.ac.uk/~nvanzuy/Onlinesupp.S1Table5.xlsx 
 
  
Page 46 of 84Diabetes
5 
 
S1 Table 6: Rs9942471 was associated (p≤5x10-8) with microalbuminuria in subjects with T2D of European descent and was not associated with any other 
dichotomous diabetic kidney disease phenotype. 
Phenotype CHR BP SNP 
Discovery Replication Joint 
EA/N
EA 
EAF 
OR 
P Ancestry EAF 
OR 
P 
OR 
P N 
(95%CI) (95%CI) (95%CI) 
Chronic kidney 
disease (CKD) 
6 89948232 rs9942471 
A/C 
0.63 
0.98 
(0.89,1.07) 
0.50 
European 0.62 
1.10 
(0.98,1.23) 
0.10 
1.02 
(0.95,1.10) 
0.41 11,897 
Asian and 
European 
0.75 
1.04 
(0.96,1.13) 
0.31 
1.01 
(0.95,1.08) 
0.60 19,236 
CKD and diabetic 
kidney disease 
(DKD) 
6 89948232 rs9942471 
A/C 
0.63 
1.06 
(0.93,1.22) 
0.32 
European 0.59 
1.20 
(0.88,1.64) 
0.45 
1.07 
(0.95,1.22) 
0.22 2,834 
Asian and 
European 
0.79 
1.10 
(0.88,1.37) 
0.50 
1.07 
(0.95,1.21) 
0.23 3,928 
All DKD 6 89948232 rs9942471 
A/C 
0.64 
1.20 
(1.12,1.29) 
4.8x10-7 
European 0.62 
1.12 
(0.98,1.27) 
0.14 
1.18 
(1.11,1.25) 
3.8x10-7 7,053 
Asian and 
European 
0.87 
1.06 
(0.98,1.15) 
0.18 
1.13 
(1.07,1.19) 
1.7x10-4 19,253 
End-stage renal 
disease (ESRD) vs 
non ESRD 
6 89948232 rs9942471 
A/C 
0.64 
0.85 
(0.71,1.05) 
0.07 
European 0.63 
1.09 
(0.88,1.36) 
0.42 
0.94 
(0.83,1.08) 
0.30 6,455 
Asian and 
European 
0.82 
1.16 
(1.00,1.36) 
0.02 
1.03 
(0.93,1.13) 
0.46 12,260 
Late DKD 6 89948232 rs9942471 
A/C 
0.63 
1.14 
(1.04,1.25) 
0.01 
European 0.62 
1.02 
(0.86,1.20) 
0.32 
1.11 
(1.02,1.20) 
0.05 5,128 
Asian and 
European 
0.88 
1.01 
(0.93,1.10) 
0.85 
1.06 
(0.99,1.13) 
0.22 19,578 
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Phenotype CHR BP SNP 
Discovery Replication Joint 
EA/N
EA 
EAF 
OR 
P Ancestry EAF 
OR 
P 
OR 
P N 
(95%CI) (95%CI) (95%CI) 
              
Microalbuminuria 6 89948232 rs9942471 
A/C 
0.64 
1.24 
(1.15,1.34) 
2.1x10-7 
European 0.59 
1.32 
(1.09,1.59) 
0.06 
1.25 
(1.16,1.34) 
4.5x10-8 4,801 
Asian and 
European 
0.85 
1.11 (0.99-
1.23) 
0.91 
1.15 
(1.08,1.23) 
1.2x10-5 5,652 
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S1Table 7: A cross comparison of top variants associated with diabetic kidney disease phenotypes in subjects with type 2 diabetes in subjects with type 1 
diabetes (Shaded) (Sandholm et al, 2017). 
Phenotype SNP EA/NEA EAF 
In subjects with type 2 diabetes In subjects with type 1 diabetes 
OR/Beta (95%CI) p OR/Beta (95%CI) p 
‘CKD’ rs2206136 (PLCB4) A/T 0.42 1.13 (1.05,1.21) 9.0×10-5 0.94 (0.85,1.04) 0.23 
‘microalbuminuria’ rs9942471 (GABRR1) A/C 0.64 1.25 (1.16,1.34) 4.50×10-8 0.93 (0.82,1.05) 0.26 
‘eGFR’ rs11864909 (UMOD) T/C 0.28 2.31 (1.54,3.09) 4.60×10-9 1.22 (-0.06,2.50) 0.07 
‘ESRD vs no ESRD' rs61277444 (PTPN13) G/A 0.09 
Not available 
1.41 (1.21,1.65) 1.90×10-6 
‘ESRD vs controls’ rs61277444 (PTPN13) G/A 0.09 1.42 (1.02,1.67) 6.00×10-6 
‘ESRD vs no ESRD’ rs7562121 (AFF3) C/G 0.23 1.12 (0.97,1.30) 0.21 1.27 (1.17,1.39) 3.50×10-7 
‘CKD+DKD’ rs1989248 (CNTNAP2) C/A 0.28 0.73 (0.61,0.87) 6.14×10-4 1.26 (1.15,1.38) 6.00×10-7 
‘ESRD vs controls’ rs1989248 (CNTNAP2) C/A 0.28 0.71 (0.57,0.88) 0.51 1.29 (1.17,1.43) 1.80×10-6 
‘All DKD’ rs72809865 (NRG3) T/C 0.16 1.11 (0.99,1.75) 0.05 1.17 (1.09,1.26) 7.40×10-6 
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S1 Table 8:  Phenotype definitions used in the combined analysis of diabetic kidney disease in subjects with type 1 diabetes or type 2 diabetes (T1D+T2D) 
Analysis Case definition Control definition 
Type 1 and 2 diabetes 
#Cases #Controls 
All Diabetic kidney disease (DKD) 
All DKD: Microalbuminuria OR OR Late DKD 
OR end-stage renal disease (ESRD) 
Normoalbuminuria (Albumin 
excretion rate [AER] <20 µg/min OR 
AER <30 mg/24 h OR ACR <2.5/3.5 
mg/mmol for men/women AND 
duration of T2D >10 years or duration 
of T1D >15 years 
5,908 4,965 
Microalbuminuria 
Microalbuminuria: At least 2 out of 3 
consecutive measurements with albumin 
excretion rate (AER) ≥20 AND <200 µg/min 
OR AER ≥30 AND <300 mg/24 hr OR 
albumin to creatinine ratio (ACR) ≥2.5/3.5 
AND <25/35 mg/mmol for men/women 
Normoalbuminuria AND duration of 
T2D >10 years or duration of T1D >15 
years 
2,795 4,831 
Late DKD 
Late DKD: At least one measurement with 
AER ≥200 µg/min OR AER ≥300 mg/24 h OR 
ACR ≥25/35 mg/mmol for men/women) or 
end-stage renal disease (ESRD, eGFR < 15 
mL/min/1.73m2 OR kidney transplantation 
OR dialysis) 
Normoalbuminuria AND duration of 
T2D >10 years or duration of T1D >15 
years 
3,096 4,965 
ESRD vs. controls 
ESRD: eGFR < 15 mL/min/1.73m2 OR 
kidney transplantation OR dialysis 
No DKD AND duration of T2D >10 
years or duration of T1D >15 years 
1,184 4,474 
ESRD vs. no ESRD ESRD (see above) 
No ESRD AND duration of T2D >10 
years or duration of T1D >15 years 
1,184 8,466 
Chronic Kidney Disease (CKD)  CKD: eGFR < 60 mL/min/1.73m2 
No CKD AND duration of T2D >10 
years or duration of T1D >15 years 
5,554 3,680 
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Analysis Case definition Control definition 
Type 1 and 2 diabetes 
#Cases #Controls 
CKD and DKD 
CKD and DKD: eGFR < 60 mL/min/1.73m2  
AND DKD 
No CKD AND no ESRD AND 
normoalbuminuria AND duration of 
T2D >10 years or duration of T1D >15 
years 
2,647 2,995 
eGFR 
eGFR: eGFR=32788 x Serum Creatinine(μmol/L)-1.154 x Agx10-.203 x [0.742 if female] 
(mL/min/1.73m2) 
13,158 eGFR 
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S1 Table 9: The discovery, replication and joint analysis of the 47 lead variants selected for replication from seven dichotomous diabetic kidney disease and 
a continuous eGFR phenotype (mL/min/1.73m2) in the combined analysis of subjects with either type 1 or type 2 diabetes 
www.well.ox.ac.uk/~nvanzuy/Onlinesupp.S1Table8.xlsx 
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S1 Table 10:  We report associations of reported diabetic kidney disease (DKD) variants with corresponding DKD phenotypes in this study at a p<0.05 
irrespective of type of diabetes.  In supplementary Figure 5 we show z scores for all DKD phenotypes from subjects with T2D and the combined analysis of 
subjects with T1D or T2D. 
PMID SNP (Gene) 
Published Current study 
Phenotype Diabetes EA EAF 
Effect 
(95%CI) 
P trait Diabetes 
Effect 
(95%CI) 
P 
15793268 
rs1800764 (ACE) 
Microalbu
minuria 
T1D C 0.46 
1.11 
(1.01,1.22) 
0.04 
‘Microalb
uminuria’ 
T2D 
0.87 
(0.78,0.97) 
0.02 
19430482 
rs12917707 
(UMOD) 
CKD - G 0.80 
1.32 
(1.24,1.4) 
5.2×10-16 ‘CKD’ 
T1D+T2D 
1.06 
(0.99,1.14) 
0.02 
T2D 
1.08 
(0.99,1.18) 
0.02 
rs12917707 
(UMOD) 
eGFR - T 0.20 
0.02 
(0.02,0.03) 
2.3×10-12 ‘eGFR’ 
T1D+T2D 
1.93 
(1.25,2.61) 
2.9×10-6 
T1D+T2D 
0.02 
(0.01,0.03) 
6.2×10-6 
T2D 
1.96 
(1.20,2.73) 
0.05 
rs17319721 
(SHROOM3) 
eGFR - A 0.44 
0.01 
(0.01,0.02) 
1.0×10-12 ‘eGFR’ T1D+T2D 
-1.11 (-
1.88,-0.34) 
4.9×10-3 
rs2467853 
(SPATAGL1) 
eGFR - G 0.39 
0.01 
(0.01,0.02) 
6.0×10-14 ‘eGFR’ T1D+T2D 
-0.95 (-
1.75,-0.149) 
0.02 
20383146 
rs7805747 
(PRKGA2) 
CKD - A 0.24 
1.18 
(1.11,1.25) 
4.0×10-12 
‘CKD’ T1D+T2D 
1.09 
(1,1.18) 
0.01 
‘CKD’ T2D 
1.10 
(0.99,1.22) 
0.03 
20962522 
rs1800783 (NOS3) DKD T1D T 0.63 
1.26 
(1.1,1.45) 
6.0×10-4 ‘all DKD’ T1D+T2D 
1.06 
(0.99,1.13) 
0.03 
 
rs5186 (AGTR1) DKD T1D+T2D A 0.74 
1.01 
(0.93,1.10) 
0.10 
‘all DKD’ T1D+T2D 
0.90 
(0.84,0.97) 
5.8×10-3 
‘all DKD’ T2D 0.90 0.02 
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PMID SNP (Gene) 
Published Current study 
Phenotype Diabetes EA EAF 
Effect 
(95%CI) 
P trait Diabetes 
Effect 
(95%CI) 
P 
(0.81,0.99) 
rs833061 (VEGFA) DKD T1D+T2D T 0.5 
2.08 
(1.64,2.65) 
0.32 ‘all DKD’ T2D 
0.91 
(0.84,0.98) 
0.03 
23028342 
rs12437854 
(RGMA/MCTP2) 
ESRD T1D G 0.06 
1.72 
(1.36,2.18) 
2.0×10-9 
‘ESRD vs 
controls’ 
T1D+T2D 
1.30 
(0.99,1.71) 
3.6×10-3 
ESRD vs 
non ESRD 
T1D+T2D 
1.40 
(1.06,1.85) 
1.2×10-3 
rs7583877 (AFF3) ESRD T1D C 0.31 
1.34 
(1.21,1.48) 
1.2×10-8 
‘ESRD vs 
controls’ 
T1D+T2D 
1.21 
(1.11,1.31) 
1.9×10-3 
‘ESRD vs 
non ESRD’ 
T1D+T2D 
1.22 
(1.13,1.32) 
4.8×10-4 
24871321 
rs12137135 
(WNT4-ZBTB40) 
ESRD T1D G 0.16 Bayesian Analysis 
‘ESRD vs 
controls’ 
T1D+T2D 
1.20 
(1.02,1.40) 
0.02 
‘ESRD vs 
non ESRD’ 
T1D+T2D 
1.23 
(1.06,1.43) 
8.1×10-3 
rs12917114 
(SEMA6D-SLC24A5) 
ESRD T1D T 0.12   
ESRD vs 
non ESRD 
T1D+T2D 
1.24 
(1.05,1.46) 
7.9×10-3 
rs1670754 (4p15) ESRD T1D A 0.19   
‘ESRD vs 
non ESRD’ 
T1D+T2D 
1.16 
(1.02,1.32) 
0.04 
rs2838302 (SIK1) ESRD T1D G 0.08   
‘ESRD vs 
controls’ 
T1D+T2D 
1.28 
(1.03,1.58) 
4.7×10-3 
‘ESRD vs 
non ESRD’ 
T1D+T2D 
1.39 
(1.12,1.74) 
3.9×10-4 
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S1 Table 11:  Results of a genetic risk score analysis of diabetic kidney disease (DKD) related risk factors and different DKD phenotypes (p<2.3x10-3) 
DKD PHENOTYPE GENETIC RISK SCORE OR(95%CI) PVAL 
T1D and T2D Late DKD Body mass index (BMI) 2.12 (1.55,2.90) 2.3×10-6 
T1D and T2D Late DKD Body mass index (z transformed) 2.04 (1.48,2.82) 1.6×10-5 
T1D and T2D All DKD Body mass index (BMI) 1.75 (1.35,2.27) 2.4×10-5 
T1D and T2D All DKD Body mass index (z transformed) 1.68 (1.28,2.19) 1.5×10-4 
T2D All DKD Body mass index (BMI) 2.02 (1.40,2.92) 1.8×10-4 
T1D and T2D CKD Body mass index (z transformed) 1.73 (1.29,2.32) 2.7×10-4 
T2D ESRD vs no ESRD Waist-Hip Ratio (BMI adj.) 4.19 (1.87,9.36) 4.8×10-4 
T1D and T2D CKD Body mass index (BMI) 1.62 (1.21,2.17) 1.3×10-3 
T2D ESRD vs no ESRD Insulin resistance (N SNPs = 10) 1.09 (1.03,1.14) 1.6×10-3 
T2D ESRD vs controls Insulin resistance (N SNPs = 10) 1.09 (1.03,1.15) 1.7×10-3 
T2D ESRD vs controls Waist-Hip Ratio (BMI adj.) 4.04 (1.69,9.66) 1.7×10-3 
T2D Late DKD Body mass index (BMI) 2.12 (1.32,3.40) 1.8×10-3 
T1D and T2D CKD and DKD Body mass index (BMI) 1.84 (1.25,2.70) 1.8×10-3 
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S1 Table 12: The Finnish Diabetic Nephropathy Study Centres 
Centre Members 
Anjalankoski Health Center S.Koivula, T.Uggeldahl 
Central Finland Central Hospital, 
Jyväskylä  
T.Forslund, A.Halonen, A.Koistinen, P.Koskiaho, 
M.Laukkanen, J.Saltevo, M.Tiihonen 
Central Hospital of Åland Islands, 
Mariehamn  
M.Forsen, H.Granlund, A.-C.Jonsson, B.Nyroos 
Central Hospital of Kanta-Häme, 
Hämeenlinna  
P.Kinnunen, A.Orvola, T.Salonen, A.Vähänen 
Central Hospital of Kymenlaakso, Kotka  R.Paldanius, M.Riihelä, L.Ryysy 
Central Hospital of Länsi-Pohja, Kemi  H.Laukkanen, P.Nyländen, A.Sademies 
Central Ostrobothnian Hospital 
District,Kokkola 
S.Anderson, B.Asplund, U.Byskata, 
P.Liedes,M.Kuusela, T.Virkkala 
City of Espoo Health Center  
Espoonlahti  A.Nikkola, E.Ritola 
Tapiola  M.Niska, H.Saarinen 
Samaria  E.Oukko-Ruponen, T.Virtanen 
City of Helsinki Health Center Viherlaakso A.Lyytinen 
Puistola  H.Kari, T.Simonen 
Suutarila  A.Kaprio, J.Kärkkäinen, B.Rantaeskola 
Töölö  P.Kääriäinen, J.Haaga, A-L.Pietiläinen 
City of Hyvinkää Health Center  S.Klemetti, T.Nyandoto, E.Rontu, S.Satuli-Autere 
City of Vantaa Health Center:  
Korso  R.Toivonen, H.Virtanen 
Länsimäki R.Ahonen, M.Ivaska-Suomela, A.Jauhiainen 
Martinlaakso  M.Laine, T.Pellonpää, R.Puranen 
Myyrmäki  A.Airas, J.Laakso, K.Rautavaara 
Rekola  M.Erola, E.Jatkola 
Tikkurila  R.Lönnblad, A.Malm, J.Mäkelä, E.Rautamo 
Heinola Health Center  P.Hentunen, J.Lagerstam 
Helsinki University Central Hospital, 
Department of Medicine, Division of 
Nephrology 
M.Feodoroff, D.Gordin, O.Heikkilä, K.Hietala, 
J.Fagerudd, M.Korolainen, L.Kyllönen, J.Kytö, 
S.Lindh, K.Pettersson-Fernholm, M.Rosengård-
Bärlund, A.Sandelin, L.Thorn, J.Tuomikangas, 
T.Vesisenaho, J.Wadén 
Herttoniemi Hospital, Helsinki  V.Sipilä 
Hospital of Lounais-Häme, Forssa  T.Kalliomäki, J.Koskelainen, R.Nikkanen, 
N.Savolainen, H.Sulonen, E.Valtonen 
Hyvinkää Hospital L. Norvio, A.Hämäläinen 
Iisalmi Hospital  E.Toivanen 
Jokilaakso Hospital, Jämsä  A.Parta, I.Pirttiniemi 
Jorvi Hospital, Helsinki University Central 
Hospital 
S.Aranko, S.Ervasti, R.Kauppinen-Mäkelin, 
A.Kuusisto, T.Leppälä, K.Nikkilä, L.Pekkonen 
Jyväskylä Health Center, Kyllö K.Nuorva, M.Tiihonen 
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Centre Members 
Kainuu Central Hospital, Kajaani S.Jokelainen, K.Kananen, M.Karjalainen, 
P.Kemppainen, A-M.Mankinen, A.Reponen, 
M.Sankari 
Kerava Health Center  H.Stuckey, P.Suominen 
Kirkkonummi Health Center  A.Lappalainen, M.Liimatainen, J.Santaholma 
Kivelä Hospital, Helsinki  A.Aimolahti, E.Huovinen 
Koskela Hospital, Helsinki  V.Ilkka, M.Lehtimäki 
Kotka Health Center  E.Pälikkö-Kontinen, A.Vanhanen 
Kouvola Health Center  E.Koskinen, T.Siitonen 
Kuopio University Hospital E.Huttunen, R.Ikäheimo, P.Karhapää, 
P.Kekäläinen,M.Laakso, T.Lakka, E.Lampainen, 
L.Moilanen, S. Tanskanen, L.Niskanen, 
U.Tuovinen, I.Vauhkonen, E.Voutilainen 
Centre Members 
Anjalankoski Health Center S.Koivula, T.Uggeldahl 
Central Finland Central Hospital, 
Jyväskylä  
T.Forslund, A.Halonen, A.Koistinen, P.Koskiaho, 
M.Laukkanen, J.Saltevo, M.Tiihonen 
Central Hospital of Åland Islands, 
Mariehamn  
M.Forsen, H.Granlund, A.-C.Jonsson, B.Nyroos 
Central Hospital of Kanta-Häme, 
Hämeenlinna  
P.Kinnunen, A.Orvola, T.Salonen, A.Vähänen 
Central Hospital of Kymenlaakso, Kotka  R.Paldanius, M.Riihelä, L.Ryysy 
Central Hospital of Länsi-Pohja, Kemi  H.Laukkanen, P.Nyländen, A.Sademies 
Central Ostrobothnian Hospital 
District,Kokkola 
S.Anderson, B.Asplund, U.Byskata, 
P.Liedes,M.Kuusela, T.Virkkala 
City of Espoo Health Center  
Espoonlahti  A.Nikkola, E.Ritola 
Tapiola  M.Niska, H.Saarinen 
Samaria  E.Oukko-Ruponen, T.Virtanen 
City of Helsinki Health Center Viherlaakso A.Lyytinen 
Puistola  H.Kari, T.Simonen 
Suutarila  A.Kaprio, J.Kärkkäinen, B.Rantaeskola 
Töölö  P.Kääriäinen, J.Haaga, A-L.Pietiläinen 
City of Hyvinkää Health Center  S.Klemetti, T.Nyandoto, E.Rontu, S.Satuli-Autere 
City of Vantaa Health Center:  
Korso  R.Toivonen, H.Virtanen 
Länsimäki R.Ahonen, M.Ivaska-Suomela, A.Jauhiainen 
Martinlaakso  M.Laine, T.Pellonpää, R.Puranen 
Myyrmäki  A.Airas, J.Laakso, K.Rautavaara 
Rekola  M.Erola, E.Jatkola 
Tikkurila  R.Lönnblad, A.Malm, J.Mäkelä, E.Rautamo 
Heinola Health Center  P.Hentunen, J.Lagerstam 
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Centre Members 
Helsinki University Central Hospital, 
Department of Medicine, Division of 
Nephrology 
M.Feodoroff, D.Gordin, O.Heikkilä, K.Hietala, 
J.Fagerudd, M.Korolainen, L.Kyllönen, J.Kytö, 
S.Lindh, K.Pettersson-Fernholm, M.Rosengård-
Bärlund, A.Sandelin, L.Thorn, J.Tuomikangas, 
T.Vesisenaho, J.Wadén 
Herttoniemi Hospital, Helsinki  V.Sipilä 
Hospital of Lounais-Häme, Forssa  T.Kalliomäki, J.Koskelainen, R.Nikkanen, 
N.Savolainen, H.Sulonen, E.Valtonen 
Hyvinkää Hospital L. Norvio, A.Hämäläinen 
Iisalmi Hospital  E.Toivanen 
Jokilaakso Hospital, Jämsä  A.Parta, I.Pirttiniemi 
Jorvi Hospital, Helsinki University Central 
Hospital 
S.Aranko, S.Ervasti, R.Kauppinen-Mäkelin, 
A.Kuusisto, T.Leppälä, K.Nikkilä, L.Pekkonen 
Jyväskylä Health Center, Kyllö K.Nuorva, M.Tiihonen 
Kainuu Central Hospital, Kajaani S.Jokelainen, K.Kananen, M.Karjalainen, 
P.Kemppainen, A-M.Mankinen, A.Reponen, 
M.Sankari 
Kerava Health Center  H.Stuckey, P.Suominen 
Kirkkonummi Health Center  A.Lappalainen, M.Liimatainen, J.Santaholma 
Kivelä Hospital, Helsinki  A.Aimolahti, E.Huovinen 
Koskela Hospital, Helsinki  V.Ilkka, M.Lehtimäki 
Kotka Health Center  E.Pälikkö-Kontinen, A.Vanhanen 
Kouvola Health Center  E.Koskinen, T.Siitonen 
Kuopio University Hospital E.Huttunen, R.Ikäheimo, P.Karhapää, 
P.Kekäläinen,M.Laakso, T.Lakka, E.Lampainen, 
L.Moilanen, S. Tanskanen, L.Niskanen, 
U.Tuovinen, I.Vauhkonen, E.Voutilainen 
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S1 Table 13:  Hong Kong Diabetes Registry TRS Project Group members. 
Group  Members 
Ronald C.W. Ma1,2,3,4 
Juliana C.N. Chan1,2,3 
Yu Huang5 
Hui-yao Lan1, 3 
Si Lok 3 
Brian Tomlinson1 
Stephen K.W. Tsui5 
Weichuan Yu6 
Kevin Y.L. Yip7 
Ting Fung Chan8 
Xiaodan Fan9 
Wing Yee So1,2 
Cheuk Chun Szeto1 
Nelson Tang3 
Andrea O. Luk1,2,3 
Xiaoyu Tian5 
Guozhi Jiang1 
Claudia H.T. Tam1 
Heung Man Lee1 
Cadmon K.P. Lim1 
Katie K.H. Chan2 
Fangying Xie1 
Alex C.W. Ng1 
Grace P.Y. Cheung1 
Ming-wai Yeung1 
Shi Mai5 
Fei Xie1 
Sen Zhang6 
Pu Yu6 
Meng Weng6 
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Affiliations 
1Department of Medicine and 
Therapeutics, The Chinese University 
of Hong Kong, Hong Kong 
2Hong Kong Institute of Diabetes and 
Obesity, The Chinese University of 
Hong Kong, Hong Kong 
3Li Ka Shing Institute of Health 
Sciences, The Chinese University of 
Hong Kong, Hong Kong 
4Integrated Bioinformatics 
Laboratory for Cancer Biology and 
Metabolic Diseases, The Chinese 
University of Hong Kong, Hong Kong 
5School of Biomedical Sciences, The 
Chinese University of Hong Kong 
6Department of Electronic and 
Computer Engineering, The Hong 
Kong University of Science and 
Technology 
7 Departent of Computer Science and 
Engineering, The Chinese University 
of Hong Kong 
8 School of Life Sciences, The Chinese 
University of Hong Kong 
9 Department of Statistics, The 
Chinese University of Hong Kong, 
Hong Kong 
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S1 Table 14:  Group membership of The Warren 3/UK GoKinD Study Group 
Centre Members 
Belfast A. P. Maxwell, A. J. McKnight, D. A. Savage 
Edinburgh J. Walker 
London S. Thomas, G. C. Viberti 
Manchester A. J. M. Boulton 
Newcastle S. Marshall 
Plymouth A. G. Demaine, B. A. Millward 
Swansea S. C. Bain 
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S1 Table 15:  Membership of the GENIE Consortium 
FinnDiane, 
Finland: 
Niina Sandholm1,2,3, Carol Forsblom1,2, Valma Harjutsalo1,2,4, Ville-Petteri Mäkinen1,2, 
4,6, Aila J Ahola1,2, Emma Dahlström1,2, Daniel Gordin1,2, Outi Heikkilä1,2, Kustaa 
Hietala1,7, Janne Kytö1,7, Markku Lehto1,2, Raija Lithovius1,2, Nicolae Mircea 
Panduru1,8, Maija Parkkonen1,2, Milla Rosengård-Bärlund1,2, Markku Saraheimo1,2, 
Jenny Söderlund1,2, Aino Soro-Paavonen1,2, Anna Syreeni1,2, Lena M Thorn1,2, Nina 
Tolonen1,2, Johan Wadén1,2, Per-Henrik Groop1,2,9 
Belfast, 
UK: 
Amy Jayne McKnight10, Gareth J. McKay10, Alexander P. Maxwell10,11 
Boston, 
MA, USA: 
Rany M. Salem12,13,14, Tamara Isakova15,16, Cameron Palmer12,13, Candace Guiducci12, 
Andrew Taylor12,17, Daniel B. Mirel12, Winfred W. Williams14,17, Joel N. 
Hirschhorn12,13,14, Jose C. Florez12,14,17 
Dublin, 
Ireland: 
Eoin P. Brennan18,19, Denise M. Sadlier18,19, Finian Martin18,19, Catherine Godson18,19 
Affiliations: 
 
1. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, 
Finland  
2. Department of Medicine, Division of Nephrology, Helsinki University Central 
Hospital, Helsinki, Finland  
3. Department of Biomedical Engineering and Computational Science, Aalto 
University, Espoo, Finland  
4. Diabetes Prevention Unit, National Institute for Health and Welfare, 
Helsinki, Finland. 
5. Department of Integrative Biology and Physiology, University of California 
Los Angeles, United States 
6. South Australian Health and Medical Research Institute, Adelaide, Australia 
7. Department of Ophthalmology, Helsinki University Central Hospital, 
Helsinki, Finland. 
8. Chair of pathophysiology, 2nd clinical Department, "Carol Davila" University 
of Medicine and Pharmacy, Bucharest, Romania. 
9. Baker IDI Heart and Diabetes Institute, Melbourne, Australia. 
10. Nephrology Research, Centre for Public Health, Queen’s University of 
Belfast, Belfast, UK. 
11. Regional Nephrology Unit, Level 11, Tower Block, Belfast City Hospital, 
Belfast, UK. 
12. Program in Medical and Population Genetics, Broad Institute, Cambridge, 
MA, USA. 
13. Endocrine Research Unit, Department of Endocrinology, Children’s Hospital, 
Boston, MA, USA. 
14. Department of Medicine, Harvard Medical School, Boston, MA, USA. 
15. Division of Nephrology and Hypertension, University of Miami, Miami, 
Florida, USA 
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S1 Table 16: DCCT/EDIC group members 
CLINIC # CLINIC NAME STUDY 
COORDINATORS 
PRINCIPAL 
INVESTIGATORS 
01 Case Western Reserve University Lynne Mayer 
 
Rose Gubitosi-Klug                    
 
02 University of Pennsylvania Patti Bourne 
 
Mark Schutta                               
 
03 Cornell University Mary Ellen Lackaye Naina Sinha Gregory  
 
04 Henry Ford Health System Davida Kruger 
J. Kimberly Jones 
 
Arti Bhan 
 
05 Joslin Diabetes Center Ellen Golden 
 
Lloyd Aiello 
 
06 Massachusetts General Hospital Mary Larkin 
 
David Nathan 
 
07 Mayo Clinic Georgia Ziegler 
 
John Service 
 
08 Med University of South Carolina Susan Caulder 
Clare Pittman 
 
Louis Luttrell 
Maria Lopes-Virella 
 
09 International Diabetes Center Mary Johnson 
Kimberly Gunyou 
 
Richard Bergenstal 
 
10 University of Iowa Brenda Vittetoe 
 
William Sivitz 
 
11 University of Minnesota Nancy Flaherty 
 
John Bantle 
 
12 University of Missouri Susan Hitt 
 
David Goldstein 
Dean Hainsworth 
 
13 University of Pittsburgh Lori Cimino 
 
Trevor Orchard 
 
14 University of Tennessee Christine Wigley 
 
Samuel Dagogo-Jack 
 
15 University of Texas Suzanne Strowig 
 
Philip Raskin 
 
16 University of Toronto Annette Barnie 
 
Bernard Zinman 
 
17 University of Washington  Robyn Fahlstrom 
 
Jerry Palmer 
 
18 University of Western Ontario Judith Harth 
Marsha Driscoll 
 
Charlotte McDonald 
 
19 Vanderbilt University 
 
Janie Lipps Hagan 
 
Michael May 
 
20 Washington University St. Louis 
 
Lucy Levandoski 
 
Neil White 
 
CLINIC # CLINIC NAME STUDY PRINCIPAL 
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COORDINATORS INVESTIGATORS 
21 Yale University Patricia Gatcomb William Tamborlane 
23 Northwestern University Daphne Adelman 
Susan Colson 
 
Mark Molitch 
24 University California San Diego Gayle Lorenzi 
 
Sunder Mudaliar 
 
25 University of MD Baltimore  Sherry 
Johnsonbaugh 
 
Ryan Miller 
 
26 University of New Mexico Janene Canady 
 
David Schade 
  
27 University of South Florida Maria Luisa Bernal 
 
John Malone 
Anthony Morrison 
41 
 
University of Michigan Catherine Martin 
 
William Herman 
Rodica Pop-Busui 
Executive 
Committee 
Title Name  
 Co-Chairman David Nathan  
 NIDDK Project Scientist Catherine Cowie  
 NIDDK Program Director Ellen Leschek  
 Lead Research Scientist Patricia Cleary  
 Principal Investigator Data 
Coordinating Center 
John Lachin  
 Vice Chairman 
Chair, P&P Committee 
Bernie Zinman  
 Principal Investigator Clinical 
Coordinating Center 
Rose Gubitosi-Klug  
 Co-Chair, Study Coordinators 
Chair, DQA Committee 
Gayle Lorenzi  
 Co-Chair, Study Coordinators Catherine Martin  
 Director Data Coordinating 
Center  
Barbara Braffett  
Central Units Title Name  
 Principal Investigator 
Project Manager 
Mike Steffes 
Valerie Arends  
 
 Director 
Principal Investigator 
Project Manager 
Lead Photographer 
Barbara Blodi 
Ronald Danis 
Daniel Lawrence 
Hugh Wabers 
 
 Director 
Senior MD Coder 
Programmer/Analyst 
Senior ECG Technician 
Assistant Project Manager 
Elsayed Soliman 
Zhu-Ming Zhang 
Charles Campbell 
Susan Hensley 
Lisa Keasler 
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S1 Table 17:  Members of the SUMMIT consortium 
Partner Name Position 
1 Michael Mark Coordinator, WP6 leader 
Boehringer-Ingelheim Markus Albertini Project manager 
Ingelheim, Germany Carine Boustany Chronic Kidney Disease, Head of Lab 
  Alexander Ehlgen Transmed 
  Martin Gerl Biomarker & Bioanlysis, Groupleader 
  Jochen Huber In vivo Scientist CMDR, Head of Lab 
  Corinna Schölch Biomarker & Bioanlysis, Head of Lab 
  Heike Zimdahl-Gelling Pharmacogenomics, Head of Lab 
      
2 Leif Groop 
Prof. Endocrinology; Coordinator Managing entity 
IMI-JU; PI; WP1 and WP6 leader 
Lund University Elisabet Agardh Prof. Ophthalmology 
Clinical Research 
Centre Emma Ahlqvist Postdoc 
Malmö, Sweden Tord Ajanki Communication strategist 
  Nibal Al Maghrabi Research nurse 
  Peter Almgren Biostatistician 
  Jan Apelqvist Diabetologist 
  Eva Bengtsson Assis. Prof. Cardiovascular research 
  Lisa Berglund Postdoc 
  Harry Björckbacka Assis. Prof. Cardiovascular research 
  Ulrika Blom-Nilsson LUDC administrator 
  Mattias Borell Website, server management 
  Agneta Burström Research nurse 
  Corrado Cilio Assoc. Prof. Cellular autoimmunity 
  Magnus Cinthio 
Assist. Prof. Electrical Measurements, Lund 
Technical University 
  Karl Dreja Nephrologist 
  Pontus Dunér Postdoc Exp. Cardiovasc. Research 
  Daniel Engelbertsen PhD student Exp. Cardiovasc. Research 
  Joao Fadista Postdoc 
  Maria Gomez Assoc. Prof. Cardiovascular disease, WP4 co-leader 
  Isabel Goncalves Assis. Prof. Cardiovascular research 
  Bo Hedblad Prof. Cardiovascular epidemiology 
  Anna Hultgårdh Prof. Vessel Wall Biology 
  Martin E. Johansson Pathologist 
  Cecilia Kennbäck Laboratory Engineer 
  Jasmina Kravic Database manager 
  Claes Ladenvall Genetic statistician 
  Åke Lernmark Prof. Type 1 diabetes and celiac disease 
  Eero Lindholm Physician, Researcher Diabetic Complications 
  Charlotte Ling Assist. Prof. Epigenetics 
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Partner Name Position 
  Holger Luthman Prof. Medical genetics 
  Olle Melander 
Assoc. Prof. Hypertension and cardiovascular 
disease 
  Malin Neptin Biomedical analyst 
  Jan Nilsson 
Prof. Experimental Cardiovascular research, WP3 
leader 
  Peter Nilsson Prof. Internal medicine 
  Tobias Nilsson 
PhD student Electrical Measurements, Lund 
Technical University 
  
Gunilla Nordin 
Fredriksson Prof. Cardiovascular research 
  Marju Orho-Melander Prof. Genetic epidemiology 
  Emilia Ottoson-Laakso PhD student 
  Annie Persson Research nurse 
  Margaretha Persson Laboratory Engineer 
  Mats-Åke Persson Database manager 
  Jacqueline Postma Project manager 
  Elisabeth Pranter Research nurse 
  Sara Rattik PhD student Exp. Cardiovasc. Research 
  Gunnar Sterner Chief physician Internal Medicine Research Unit 
  Lilian Tindberg Research nurse 
  Maria Wigren Postdoc Exp. Cardiovasc. Research 
  Anna Zetterqvist PhD student 
  Mikael Åkerlund Postdoc 
  Gerd Östling Laboratory Engineer 
      
3 Timo Kanninen Technical director; PI 
Biocomputing 
Platforms  Anni Ahonen-Bishopp Software development manager 
(BC Platforms) Anita Eliasson Financial and administrative director 
Espoo, Finland Timo Herrala System (server) specialist 
  Päivi Tikka-Kleemola Service manager 
      
4 Anders Hamsten 
Prof. Cardiovascular disease; Atherosclerosis 
Research Unit; PI 
Karolinska Institute Christer Betsholtz Prof. Vascular biology 
Stockholm, Sweden Ami Björkholm Administrator 
  Ulf de Faire Professor emeritus Cardiovascular epidemiology 
  Fariba Foroogh Research engineer 
  Guillem Genové Scientist 
  Karl Gertow Research Assist. Prof. Cardiovascular genetics 
  Bruna Gigante Assoc. Professor Cardiovascular epidemiology 
  Bing He Postdoc 
  Karin Leander Assoc. Professor Cardiovascular epidemiology 
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Partner Name Position 
  Olga McLeod Postdoc 
  Maria Nastase-Mannila Postdoc 
  Jaako Patrakka Postdoc 
  Angela Silveira Assoc. Prof. Cardiovascular genetics 
  Rona Strawbridge Postdoc 
  Karl Tryggvason Prof. Medical Chemistry 
  Max Vikström Statistician 
  John Öhrvik Professor 
  Anne-May Österholm  Postdoc 
      
5 Barbara Thorand Nutritional scientist, epidemiologist 
Helmholtz Centre Christian Gieger Statistician 
Munich, Germany Harald Grallert Biologist 
  Tonia Ludwig Statistician 
  Barbara Nitz Scientist 
  Andrea Schneider Data manager 
  Rui Wang-Sattler Scientist 
  Astrid Zierer Statistician 
      
6 Giuseppe Remuzzi Institute director; PI 
Mario Negri Institute 
for  Ariela Benigni Head of department Molecular Medicine 
Pharmacological 
Research Roberta Donadelli Scientist 
  Maria Domenica Lesti Researcher 
Bergamo, Italy Marina Noris 
Head Laboratory Immunology and genetics of 
transplantation and rare diseases 
  Norberto Perico Senior scientist 
  Annalisa Perna Biostatistician 
  Rossella Piras Postdoc 
  Piero Ruggenenti 
Head of department Renal medicine, Assist. Prof. 
Nephrology and dialysis 
  Erica Rurali Postdoc 
      
7 
David Dunger (att: Jane 
Horsford) Prof. Paediatrics; PI 
University of 
Cambridge Ludo Chassin Senior Data Manager 
UK Neil Dalton, London Clinical biochemistry 
  John Deanfield, London Paediatric cardiology 
  Jane Horsford PA to Prof. Dunger 
  Clare Rice Operations manager/financial contact 
  James Rudd Cardiovascular imaging 
  Neil Walker Head Data services 
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Partner Name Position 
  Karen Whitehead Technician 
  Max Wong Postdoc 
      
8 Helen Colhoun 
Prof. Public health and epidemiology; PI; Vice 
coordinator Managing entity; WP2 leader 
  Fiona Adams   
University of Dundee Tahira Akbar PA to Helen Colhoun 
Scotland Jill Belch Prof. Vasucular disease 
  Harshal Deshmukh PhD student 
  Fiona Dove   
  Angela Ellingford 
NHS Tayside Diabetic Retinopathy Screening 
Programme manager 
  Bassam Farran Statistician 
  Mike Ferguson 
Dean of research Biological chemistry and drug 
discovery 
  Gary Henderson   
  Graeme Houston Consultant radiologist/senior lecturer 
  Faisel Khan 
Reader, Vascular & Inflammatory Diseases 
Research Unit 
  Graham Leese Consultant diabetologist/reader 
  Yiyuan Liu PhD student 
  Shona Livingstone Senior statistician 
  Helen Looker Epidemiologist 
  Margaret McCann Project assistant  
  Stuart McGurnaghan Lead data programmer 
  Andrew Morris Prof. Diabetic medicine 
  David Newton   
  Colin Palmer Prof. Pharmacogenomics 
  Ewan Pearson Consultant diabetologist/senior lecturer 
  Gillian Reekie Research Nurse 
  Natalie Smith Research Nurse 
      
9 Angela Shore Prof. Cardiovascular Science, PI 
Peninsula Medical 
School Kuni Aizawa Postdoc 
Exeter, UK Claire Ball Research nurse 
  Nick Bellenger Cardiologist 
  Francesco Casanova Associate Research Fellow Vascular medicine 
  Tim Frayling Prof. Genetics 
  Phil Gates Senior lecturer Cardiovascular science 
  Kim Gooding Postdoc Vascular medicine 
  Andrew Hatttersley Prof. Molecular medicine 
  Roland Ling Consultant opthalmologist 
  David Mawson Research technician 
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Partner Name Position 
  Robin Shandas Prof. Bioengineering (Colorado) 
  David Strain Stroke physician, clinical lecturer 
  Clare Thorn Postdoc Vascular medicine 
      
10 Ulf Smith Prof. ; PI 
University of 
Gothenburg Ann Hammarstedt Researcher Molecular and clinical medicine 
Sweden Hans Häring Prof. University of Tübingen 
  Oluf Pedersen Prof. Steno Centre, Copenhagen 
  Georgio Sesti Prof. Universtiy of Catanzaro 
      
11 Per-Henrik Groop Prof. Diabetes genetics; PI 
  Emma Fagerholm PhD student, genetics 
Folkhälsan Carol Forsblom Clinical coordinator 
Helsinki, Finland Valma Harjutsalo   
  Maikki Parkkonen Laboratory manager 
  Niina Sandholm DSc(PhD); GWAS and bioinformatics 
  Nina Tolonen MD PhD 
  Iiro Toppila BSc, bioinformatician 
  Erkka Valo MSc, bioinformatician 
      
12 Veikko Salomaa Prof. Epidemiology; PI; deputy leader WP2 
The National Institute 
for Health and 
Welfare Aki Havulinna DSc. (tech), statistician 
Helsinki, Finland Kati Kristiansson Postdoc 
  Pia Okamo THL press officer 
  Tomi Peltola   
  Markus Perola Professor 
  Arto Pietilä Statistician 
  Samuli Ripatti Professor, Statistics 
  Marketta Taimi Research assistant 
      
13 Seppo Ylä-Herttuala Prof.; PI; WP4 leader 
University of Eastern 
Finland Mohan Babu PhD student 
Kuopio, Finland Marike Dijkstra PhD student 
  Erika Gurzeler PhD student 
  Jenni Huusko PhD student 
  Ivana Kholová Postdoc 
  Markku Laakso Prof.  
  Mari Merentie PhD student 
  Marja Poikolainen PA Prof Ylä-Herttuala 
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Partner Name Position 
      
14 Mark McCarthy 
Prof. Human type 2 diabetes; Oxford Centre for 
Diabetes, Endocrinology and Metabolism; 
Wellcome Trust Centre for Human Genetics; PI; 
deputy leader WP1 
University of Oxford Chris Groves Technical staff 
UK Thorhildur Juliusdottir PhD student 
  Fredrik Karpe PI OCDEM 
  Vasiliki Lagou Postdoc 
  Andrew Morris 
Wellcome Trust Senior Fellow; Bioinformatics and 
statistical genetics 
  Will Rayner Database manager 
  Neil Robertson Informatics 
  Natalie van Zuydam Postdoc 
      
15 Claudio Cobelli Prof. ; PI; WP5 leader 
University of Padova Barbara Di Camillo Assist. Prof.  
Italy Francesca Finotello PhD student 
  Francesco Sambo Postdoctoral fellow 
  Gianna Toffolo Prof.  
  Emanuele Trifoglio PhD student 
      
16 Riccardo Bellazzi Prof. Bioengineering; PI; deputy leader WP5 
  Nicola Barbarini Postdoctoral fellow 
University of Pavia Mauro Bucalo Software engineer 
Italy Christiana Larizza Assist. Prof.  
  Paolo Magni Assoc. Prof. 
  Alberto Malovini Postdoctoral fellow 
  Simone Marini Postdoctoral fellow 
  Francesca Mulas Postdoctoral fellow 
  Silvana Quaglini Prof. 
  Lucia Sacchi Assist. Prof.  
  Francesca Vitali   
      
17 Ele Ferrannini Prof. Medicine; PI 
  Beatrice Boldrini Postdoctoral fellow 
University of Pisa Michaela Kozakova Senior investigator Medical Pathophysiology 
Italy Andrea Mari  
Senior researcher Biomedical engineering (ISIB-
CNR, Padova) 
  Carmela Morizzo Biologist, Sonographer Cardiovascular ultrasound 
  Lucrecia Mota EGIR administrative office 
  Andrea Natali Assoc. Prof. Medicine 
  Carlo Palombo Assoc. Prof. Medicine; deputy leader WP3 
  Elena Venturi Researcher 
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Partner Name Position 
  Mark Walker  
Prof. Molecular diabetic medicine (Univ 
Newcastle-upon-Tyne ) 
      
18 Carlo Patrono Prof.Pharmacology; PI 
Catholic University of 
Rome Francesca Pagliaccia PhD student 
Italy Bianca Rocca Assist. Prof. Pharmacology 
      
19 Pirjo Nuutila Prof. ; PI 
University of Turku Johanna Haukkala PhD student 
Finland Juhani Knuuti Prof. ; Director Turku PET Centre 
  Anne Roivainen Prof. 
  Antti Saraste Adj. Prof.  
      
20 Paul McKeague Prof. Genetic Epidemiology; PI 
University of 
Edinburgh Norma Brown Research administrator, Public Health Services 
Scotland Marco Colombo Bioinformaticist 
      
21 Birgit Steckel-Hamann Deputy coordinator; PI, Manager IMI, LRL 
Eli Lilly Krister Bokvist Biostatistician 
  Sudha Shankar Diabetologist 
  Melissa Thomas Translational Science 
      
22 Li-ming Gan 
Prof.; Translational Science Director Cardiovascular 
Disease; PI, WP3 leader 
AstraZeneca Suvi Heinonen  PhD, Internal AZ postdoc, Bioscience 
  
Ann-Cathrine Jönsson-
Rylander 
PhD, Assoc. Prof., Team Leader Bioscience, WP4 
leader 
  Remi Momo Postdoctoral fellow 
  Volker Schnecke Informatician Translational Science, WP5 leader 
  
Robert Unwin 
Translational Science Director Diabetic 
Nephropathy 
  Anna Walentinsson Geneticist Translational Science 
  Carl Whatling Bioscientist 
      
23 Everson Nogoceke 
Pre-clinical and clinical aspects of metabolic and 
vascular disease; PI;  WP2 leader 
Roche Gonzalo Durán Pacheco Senior Research Statistician 
  Ivan Formentini Biomarker & Experimental Medicine Leader  
  Thomas Schindler Pre-clinical and clinical and clinical biomarkers  
      
24 Piero Tortoli  Professor of Electronics 
University of Florence Luca Bassi Postdoctoral fellow 
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Partner Name Position 
  Enrico Boni Postdoctoral fellow 
  Alessandro Dallai Postdoctoral fellow 
  Francesco Guidi Technician 
  Matteo Lenge PhD student 
  Riccardo Matera PhD student 
  Alessandro Ramalli PhD student 
  Stefano Ricci Assist. Prof.  
  Jacopo Viti PhD student 
      
25 Bernd Jablonka SAD internal IMI coordinator 
Sanofi-aventis Dan Crowther Biomarker researcher 
  Johan Gassenhuber Biostatistician 
  Sibylle Hess Biomarker researcher 
  Thomas Hübschle Pharmacologist Diabetes 
  Hans-Paul Juretschke Imaging 
  Hartmut Rütten Head Translational Medicine 
  Thorsten Sadowski Pharmacologist Diabetes 
  Paulus Wohlfart Pharmacologist Diabetes 
      
26 Julia Brosnan 
Biochemist, (pre)clinical research CVD, Pfizer US; 
WP2 leader 
Pfizer Valerie Clerin Cardio-renal biologist, WP2 
  Eric Fauman Computational biologist 
  Craig Hyde Statistician 
  Anders Malarstig Human genetics, Pfizer Europé; WP1 leader 
  Nick Pullen Renal Disease Research Director 
  Mera Tilley   
  Theresa Tuthill Imaging specialist 
  Ciara Vangjeli 
Cardiovascular genetic epidemiologist, Pfizer 
Europe 
  Daniel Ziemek Computational biologist 
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Figures 
 
S1 Figure 1: Histogram of estimated glomerular filtration rate in the Genetics of Diabetes and Audit 
Research in Tayside Scotland study (N=6,335) shows an approximately normal distribution. 
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S1 Figure 2:  Power calculations were performed for a range of OR (1.05-2.00) and a range of minor allele 
frequencies (0.08-0.50) in A:  5,908 diabetic kidney disease cases (DKD) and 4,965 controls with no history 
of DKD with either T2D or T1D to detect an association with a candidate gene  α =  0.05/55 = 9x10-4); B: 
5,908 DKD and 4,965 controls with no history of DKD with either T2D or T1D to  detect an association at α 
= 5x10-8 and C:  3,345 DKD cases and 2,372 controls with no history of DKD in  subjects with T2D to detect 
associations at α = 5x10-8. 
 
A 
C 
B 
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S1 Figure 3:  Manhattan and QQ plots of discovery p values for chronic kidney disease(CKD, plots A and B), CKD and 
diabetic kidney disease (DKD, plots C and D), ‘all DKD’ (plots E and F), end-stage renal disease  compared to 
normoalbuminuric controls (ESRD, plots G and H), ESRD compared to normoalbuminuric controls and all other forms 
of DKD (plots J and K), ‘late DKD’ (plots L and M), microalbuminuria (plots N and P) and estimated glomerular 
filtration rate (plots Q and R) from the analysis of subjects with type 2 diabetes.  Orange peaks represent signals 
selected for replication.   
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S1 Figure 4:  Manhattan and QQ plots for chronic kidney disease (CKD, plots A and B), CKD and diabetic 
kidney disease (DKD, plots C and D), ‘all DKD’ (plots E and F), end-stage renal disease  compared to 
normoalbuminuric controls (ESRD, plots G and H), ESRD compared to normoalbuminuric controls and all 
other forms of DKD (plots J and K),  ‘late DKD’ (plots L and M), microalbuminuria (plots N and P) and 
estimated glomerular filtration rate (plots Q and R) from the combined analysis of subjects with type 1 
diabetes and type 2 diabetes.  Orange peaks represent signals selected for replication.   
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C 
S1 Figure 5: Two genome-wide significant (p<5x10-8) loci for eGFR from the combined analysis of 
subjects with either type 1 or type 2 diabetes.  These loci map to two signals in UMOD and PRKAG2 
respectively (A and B).  The Locuszoom plots show the locus specific association signal and the forest 
plots (C and D) the individual study effects or the top SNP. 
A B 
D 
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S1 Figure 6: Sixty-one loci have been reported for diabetic kidney disease (DKD) in the literature.  In this study we had summary statistics for 55 of these 
loci.  The lattice plot shows the z score for the reported loci aligned to the   risk or trait raising allele of the original report.  The plot also reflects whether 
the original report was from subjects  with diabetes (T1D+T2D,T1D or T2D) or  irrespective of diabetes status (type of diabetes not indicated).
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